Department of Rheumatology and Immunology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.
Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China, Beijing, China.
Front Immunol. 2023 Feb 23;14:1093233. doi: 10.3389/fimmu.2023.1093233. eCollection 2023.
Ankylosing spondylitis (AS) is the prototype of a group of systemic inflammatory diseases referred to as spondyloarthritis. Comorbid inflammatory bowel disease and changed gut microbiota in AS have attracted attention to the influence of gut-joint axis and encouraged treating AS by targeting gut microbiota. Here we first reported a patient with refractory AS and comorbid ulcerative colitis (UC) who underwent three fecal microbiota transplantations (FMTs). Inadequate response to conventional treatments including tumor necrosis factor inhibitors impelled FMT as alternative therapy. Notable improvements in AS and UC accompanied with changed fecal microbiota were recorded at 1 week post-FMT1. Further recovery was found after the other two FMTs, and a roughly stable status was maintained in the follow-up period. More studies are needed to validate the effectiveness of FMT in AS and its mechanisms.
强直性脊柱炎(AS)是一类被称为脊柱关节炎的系统性炎症性疾病的原型。AS 合并炎症性肠病和肠道微生物群改变引起了人们对肠道-关节轴的影响的关注,并促使人们通过靶向肠道微生物群来治疗 AS。在这里,我们首次报道了一例难治性 AS 合并溃疡性结肠炎(UC)的患者,该患者接受了三次粪便微生物群移植(FMT)。包括肿瘤坏死因子抑制剂在内的常规治疗反应不佳促使进行 FMT 作为替代治疗。FMT1 后 1 周记录到 AS 和 UC 显著改善,同时粪便微生物群发生改变。在另外两次 FMT 后发现了进一步的恢复,在随访期间保持了大致稳定的状态。需要更多的研究来验证 FMT 在 AS 中的有效性及其机制。